Exchange Traded Concepts LLC Raises Holdings in Agenus Inc. (NASDAQ:AGEN)

Exchange Traded Concepts LLC lifted its position in Agenus Inc. (NASDAQ:AGEN) by 52.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,543 shares of the biotechnology company’s stock after purchasing an additional 9,422 shares during the quarter. Exchange Traded Concepts LLC owned about 0.13% of Agenus worth $151,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Point72 DIFC Ltd purchased a new position in shares of Agenus in the 2nd quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Agenus in the second quarter worth about $106,000. Hennion & Walsh Asset Management Inc. grew its position in Agenus by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 13,604 shares in the last quarter. Blair William & Co. IL bought a new stake in Agenus during the second quarter worth approximately $441,000. Finally, Squarepoint Ops LLC purchased a new stake in Agenus during the second quarter valued at approximately $614,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Stock Down 0.2 %

Shares of AGEN stock opened at $4.49 on Wednesday. The business has a 50-day simple moving average of $5.15 and a 200-day simple moving average of $9.25. The stock has a market cap of $94.29 million, a PE ratio of -0.34 and a beta of 1.37. Agenus Inc. has a 52-week low of $4.18 and a 52-week high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million for the quarter, compared to analysts’ expectations of $64.73 million. During the same quarter in the prior year, the company earned ($4.00) earnings per share. Sell-side analysts anticipate that Agenus Inc. will post -10.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on AGEN shares. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. B. Riley lowered their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. William Blair downgraded Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. Finally, HC Wainwright lowered shares of Agenus from a “buy” rating to a “neutral” rating and decreased their price target for the company from $40.00 to $9.00 in a research report on Thursday, July 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.50.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.